Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions.

Children with immune thrombocytopenia (ITP) are often managed using a watch-and-wait approach to avoid conventional treatment that may be poorly tolerated. However, in some patients, this approach may lead to lifestyle restrictions due to risk of injury-related bleeding. Eltrombopag is a well-tolerated new option that may help these children.